相似文献
1
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments.
Clin Mol Hepatol. 2023 Feb;29(Suppl):S150-S156. doi: 10.3350/cmh.2022.0362. Epub 2023 Jan 25.
2
Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
World J Gastroenterol. 2019 Mar 21;25(11):1307-1326. doi: 10.3748/wjg.v25.i11.1307.
3
Liver fibrosis markers of nonalcoholic steatohepatitis.
World J Gastroenterol. 2015 Jun 28;21(24):7427-35. doi: 10.3748/wjg.v21.i24.7427.
4
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Gastroenterology. 2019 Apr;156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18.
5
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis.
Clin Mol Hepatol. 2023 Feb;29(Suppl):S228-S243. doi: 10.3350/cmh.2022.0401. Epub 2022 Dec 14.
6
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004.
7
Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease.
Dis Markers. 2022 Jun 29;2022:1254014. doi: 10.1155/2022/1254014. eCollection 2022.
8
Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
Metabolism. 2016 Aug;65(8):1087-95. doi: 10.1016/j.metabol.2016.01.013. Epub 2016 Feb 2.
9
Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
Cells. 2019 Aug 7;8(8):845. doi: 10.3390/cells8080845.
10
Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Eur J Gastroenterol Hepatol. 2019 May;31(5):633-641. doi: 10.1097/MEG.0000000000001385.
引用本文的文献
1
Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis.
Sci Rep. 2025 Aug 30;15(1):31982. doi: 10.1038/s41598-025-17396-1.
2
Metabolic and hepatic biomarkers associated with MASLD in the Chinese population.
Sci Rep. 2025 Aug 27;15(1):31593. doi: 10.1038/s41598-025-17219-3.
3
MOFI-FL, a novel score for detecting hepatic steatosis and predicting cardiometabolic mortality.
Sci Rep. 2025 Aug 19;15(1):30363. doi: 10.1038/s41598-025-15487-7.
4
L-Phenylalanine promotes liver steatosis by inhibiting BNIP3-mediated mitophagy.
Mol Med. 2025 Jun 30;31(1):250. doi: 10.1186/s10020-025-01303-5.
5
Associations Between Shift Work, Sociodemographic and Lifestyle Characteristics, Body Measurements, and MASLD.
Life (Basel). 2025 Jun 16;15(6):961. doi: 10.3390/life15060961.
6
Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective.
Diabetes Obes Metab. 2025 Jun;27 Suppl 4(Suppl 4):3-20. doi: 10.1111/dom.16496. Epub 2025 Jun 2.
7
Development and Validation of a Risk Prediction Model Based on Inflammatory and Nutritional Composite Indicators for Posthepatectomy Liver Failure Following Radical Resection of Hepatocellular Carcinoma.
J Inflamm Res. 2025 Apr 18;18:5261-5279. doi: 10.2147/JIR.S515918. eCollection 2025.
8
Construction and evaluation of a diagnostic model for metabolic dysfunction-associated steatotic liver disease based on advanced glycation end products and their receptors.
Front Med (Lausanne). 2025 Mar 28;12:1539708. doi: 10.3389/fmed.2025.1539708. eCollection 2025.
9
Atherogenic index of plasma identifies subjects with severe liver steatosis.
Sci Rep. 2025 Mar 17;15(1):9136. doi: 10.1038/s41598-025-93141-y.
10
Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults.
Gut Liver. 2025 Jan 15;19(1):116-125. doi: 10.5009/gnl240323. Epub 2024 Dec 6.
本文引用的文献
1
A Reappraisal of the Diagnostic Performance of B-Mode Ultrasonography for Mild Liver Steatosis.
Am J Gastroenterol. 2023 May 1;118(5):840-847. doi: 10.14309/ajg.0000000000002020. Epub 2022 Sep 21.
2
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach.
Clin Mol Hepatol. 2022 Oct;28(4):841-850. doi: 10.3350/cmh.2022.0239. Epub 2022 Sep 19.
3
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults.
Clin Mol Hepatol. 2022 Oct;28(4):814-826. doi: 10.3350/cmh.2022.0099. Epub 2022 Jun 9.
4
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.
Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.
5
Recent advances in nonalcoholic fatty liver disease metabolomics.
Clin Mol Hepatol. 2021 Oct;27(4):553-559. doi: 10.3350/cmh.2021.0127. Epub 2021 Jun 8.
6
Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance.
Ann Transl Med. 2020 Nov;8(21):1414. doi: 10.21037/atm-20-2951.
7
Comparative Assessment and External Validation of Hepatic Steatosis Formulae in a Community-Based Setting.
J Clin Med. 2020 Sep 3;9(9):2851. doi: 10.3390/jcm9092851.
8
Recent research trends and updates on nonalcoholic fatty liver disease.
Clin Mol Hepatol. 2019 Mar;25(1):1-11. doi: 10.3350/cmh.2018.0037. Epub 2018 Aug 8.
9
NAFL screening score: A basic score identifying ultrasound-diagnosed non-alcoholic fatty liver.
Clin Chim Acta. 2017 Dec;475:44-50. doi: 10.1016/j.cca.2017.09.020. Epub 2017 Sep 28.
10
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
Zotero 插件